Seeking Alpha

Eli Lilly (LLY -4.65%) shares are taking a hit this morning after the FDA delayed approving a...

Eli Lilly (LLY -4.65%) shares are taking a hit this morning after the FDA delayed approving a diabetes treatment in the final stages of development in order to further study a safety issue. The surprise move is also bleeding shares of partners Amylin (AMLN -51.4%) and Alkermes (ALKS -27.2%).
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs